These findings agree with previous reports identifying EGR1 as an important activator of p21 in glioma and gastric, colon, prostate, and breast cancer (Escoubet-Lozach et al., 2009; Kim et al., 2007, 2014; Parra et al., 2011; Shin et al., 2010,2012). Here, CDKN1A is linked to glioma.